Clinical Trials Logo

Small Lymphocytic Lymphoma clinical trials

View clinical trials related to Small Lymphocytic Lymphoma.

Filter by:

NCT ID: NCT01804686 Enrolling by invitation - Clinical trials for Chronic Lymphocytic Leukemia

A Long-term Extension Study of PCI-32765 (Ibrutinib)

CAN3001
Start date: September 9, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.

NCT ID: NCT01787409 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

Start date: March 6, 2013
Phase: N/A
Study type: Interventional

This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.

NCT ID: NCT01754857 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

Start date: November 12, 2013
Phase: Phase 2
Study type: Interventional

The investigators propose a treatment strategy where patients are treated with induction chemoimmunotherapy consisting of rituximab + bendamustine for 6 cycles, followed by initiation of maintenance rituximab and lenalidomide among patients achieving an objective response (i.e., at least stable disease with some tumor shrinkage) to induction therapy. The goal of maintenance therapy will be to capitalize on the cytoreduction following induction chemotherapy with a maintenance regimen that has also shown promising activity in CLL, in order to allow for improved PFS in this population.

NCT ID: NCT01744912 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Start date: November 21, 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether ublituximab in combination with lenalidomide (Revlimid®) is safe and effective in patients with B-Cell Lymphoid Malignancies who have relapsed or are refractory after CD20 directed antibody therapy.

NCT ID: NCT01728207 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Start date: March 2013
Phase: Phase 1
Study type: Interventional

IMMU-114 will be studied at different dose schedules and dose levels in order to assess the highest dose safely tolerated. IMMU-114 will be administered subcutaneously (under the skin). IMMU-114 will be given 1-2 times weekly for 3 weeks followed by one week of rest. This is considered one cycle. Treatment cycles will be repeated until toxicity or worsening of disease.

NCT ID: NCT01724346 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Start date: August 28, 2012
Phase: Phase 3
Study type: Interventional

An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlorambucil)

NCT ID: NCT01722487 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Start date: March 2013
Phase: Phase 3
Study type: Interventional

A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.

NCT ID: NCT01699152 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Start date: September 2012
Phase: Phase 1
Study type: Interventional

This is a multi-center, open-label, dose escalation study.

NCT ID: NCT01682616 Completed - Clinical trials for Chronic Lymphocytic Leukemia

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Start date: July 25, 2012
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, open-label, multicenter study evaluating the safety and tolerability of ABT-199 in combination with rituximab in up to 50 subjects with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. The primary objectives of this study are to assess the safety profile, to determine the maximum tolerated dose and establish the Recommended Phase Two Dose of ABT-199 when administered in combination with rituximab. The dose escalation portion of the study will include approximately 30 subjects. Once the recommended phase two dose and schedule have been determined, up to 20 additional subjects will be enrolled in an expanded safety portion of the study. Subjects who meet criteria for CR, CRi, or MRD-negative PR during the study may discontinue ABT 199. If disease progression occurs, as defined by iwCLL NCI/WG criteria for tumor response, or MRD progression, subjects may re-initiate ABT-199.

NCT ID: NCT01650727 Completed - Clinical trials for Chronic Lymphocytic Leukemia

A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)

Start date: October 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum-tolerated dose (MTD) of dinaciclib therapy in combination with rituximab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).